Survey Report: Primary Care Perspectives on GLP-1 Prescriptions
What do doctors think of GLP-1s? New survey reveals prescription trends, patient safety concerns, and how telehealth prescribers affect care amidst rising demand for weight loss medications.
Amid access issues and cost concerns surrounding GLP-1 weight loss medications, their popularity continues to surge in the U.S. One in eight Americans have used a GLP-1, while researchers estimate that 129 million Americans are eligible for semaglutide, one of the GLP-1 medications for weight management. As demand skyrockets, the healthcare industry has seen a sharp increase in third-party telehealth providers offering GLP-1 prescriptions to patients.
In some cases, this takes place without the knowledge or involvement of patients’ primary care physicians (PCPs), complicating a main function of primary care, which is to oversee care coordination, and prevent and treat chronic diseases like obesity. PCPs are a bedrock of healthcare, managing complex relationships with patients, learning each individual’s unique medical history, and addressing comorbidities. As GLP-1s continue to shape a new normal in obesity treatment, how do PCPs think third-party telehealth prescribing1 of GLP-1s will impact patient care?
As a virtual care provider that works to complement primary care, Omada is committed to supporting our members and, consequently, the skilled PCPs that work with them. In an effort to better understand the attitudes of PCPs at this pivotal moment, Omada Health surveyed over 2,000 PCPs in partnership with Sermo. Download the full report to learn more about what we found.